Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension

Mizuki Momoi, Takahiro Hiraide, Yoshiki Shinya, Hiromi Momota, Shogo Fukui, Michiyuki Kawakami, Keiichi Fukuda, Masaharu Kataoka

Research output: Contribution to journalArticlepeer-review

Abstract

The effective therapy for pulmonary arterial hypertension (PAH) with inadequate clinical response is scarce except for lung transplantation when prostacyclin infusion is ineffective. The purpose of this study is to investigate the efficacy and safety of selexipag in addition to the infusion of prostacyclin. Nine patients [median 38 (36–49) years of age; 78% female] with PAH whose clinical response was inadequate despite the use of prostacyclin infusion analogs, were evaluated. Addition of selexipag significantly improved hemodynamics and no serious adverse events were observed. Selexipag with prostacyclin infusion analogs can be an effective therapeutic strategy for the PAH patients with inadequate clinical response.

Original languageEnglish
Article number101592
JournalRespiratory Medicine Case Reports
Volume36
DOIs
Publication statusPublished - 2022 Jan
Externally publishedYes

Keywords

  • Drug combinations
  • Prostacyclin
  • Selexipag

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this